npj Breast Cancer

Papers
(The H4-Index of npj Breast Cancer is 30. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer281
Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies167
HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now122
Triple negative breast cancer: Pitfalls and progress108
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group104
Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond101
Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer96
Evolution of HER2-low expression from primary to recurrent breast cancer90
Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group85
Immunotherapy for early triple negative breast cancer: research agenda for the next decade64
Connected-UNets: a deep learning architecture for breast mass segmentation60
Immunotherapy in breast cancer: an overview of current strategies and perspectives59
ARe we there yet? Understanding androgen receptor signaling in breast cancer56
Interaction between CD36 and FABP4 modulates adipocyte-induced fatty acid import and metabolism in breast cancer47
HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment46
Upregulation of lipid metabolism genes in the breast prior to cancer diagnosis45
Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy41
PARP inhibition in breast cancer: progress made and future hopes41
Circulating tRNA-derived small RNAs (tsRNAs) signature for the diagnosis and prognosis of breast cancer41
Evidence-based guidelines for managing patients with primary ER+ HER2− breast cancer deferred from surgery due to the COVID-19 pandemic40
The acute effects of adjuvant radiation and chemotherapy on peripheral blood epigenetic age in early stage breast cancer patients37
The impact of lymphedema on health-related quality of life up to 10 years after breast cancer treatment36
Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma35
Large language model (ChatGPT) as a support tool for breast tumor board35
Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer33
Breast cancer dormancy: need for clinically relevant models to address current gaps in knowledge33
Dynamic contrast-enhanced breast MRI features correlate with invasive breast cancer angiogenesis32
Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer32
Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups31
Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL30
Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort30
Overweight and prognosis in triple-negative breast cancer patients: a systematic review and meta-analysis30
Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer30
Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors30
0.031261920928955